openPR Logo
Press release

Myocardial Infarction Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | NuvOx Pharma, Ever Supreme Bio Technology, R-Pharm, Athera Biotechnologies,

05-20-2024 09:09 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Myocardial Infarction Pipeline Assessment, 2024 Updates |

Myocardial Infarction pipeline constitutes 45+ key companies continuously working towards developing 50+ Myocardial Infarction treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Myocardial Infarction Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myocardial Infarction Market.

The Myocardial Infarction Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Myocardial Infarction Pipeline Report: https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Myocardial Infarction treatment therapies with a considerable amount of success over the years. Myocardial Infarction Key players such as - NuvOx Pharma, Ever Supreme Bio Technology, R-Pharm, Athera Biotechnologies, Celecor Therapeutics, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, and others, are developing therapies for the Myocardial Infarction treatment
• Myocardial Infarction Emerging therapies such as - NVX 308, UMSC01, RPH-104, ATH3G10, Zalunfiban, FDY-5301, Selatogrel, and others are expected to have a significant impact on the Myocardial Infarction market in the coming years.
• In April 2024, The EMPACT-MI phase III clinical trial indicated a 10% relative risk reduction in the primary composite endpoint of time to first hospitalization for heart failure or all-cause mortality for Jardiance® (empagliflozin) compared to placebo, although this did not achieve statistical significance. Jardiance was administered to adults within 14 days of an acute myocardial infarction, or heart attack, and showed a reassuring safety profile in this group. Additional pre-specified exploratory analyses revealed a 23% relative risk reduction for the time to first hospitalization due to heart failure and a 33% reduction in total hospitalizations for heart failure with Jardiance versus placebo.

Myocardial Infarction Overview
Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow to a part of the heart muscle is blocked for an extended period, causing damage or death to the heart tissue. This blockage is typically due to a buildup of fatty deposits, including cholesterol, which form plaques in the coronary arteries. When a plaque ruptures, it can create a clot that obstructs blood flow.

Get a Free Sample PDF Report to know more about Myocardial Infarction Pipeline Assessment-
https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myocardial Infarction Pipeline Therapeutics Assessment
• Myocardial Infarction Assessment by Product Type
• Myocardial Infarction By Stage and Product Type
• Myocardial Infarction Assessment by Route of Administration
• Myocardial Infarction By Stage and Route of Administration
• Myocardial Infarction Assessment by Molecule Type
• Myocardial Infarction by Stage and Molecule Type

DelveInsight's Myocardial Infarction Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Myocardial Infarction product details are provided in the report. Download the Myocardial Infarction pipeline report to learn more about the emerging Myocardial Infarction therapies

Emerging Myocardial Infarction Drugs Under Different Phases of Clinical Development Include:
• NVX 308: NuvOx Pharma
• UMSC01: Ever Supreme Bio Technology
• RPH-104: R-Pharm
• ATH3G10: Athera Biotechnologies
• Zalunfiban: Celecor Therapeutics
• FDY-5301: Faraday Pharmaceuticals
• Selatogrel: Idorsia Pharmaceuticals

Myocardial Infarction Pipeline Analysis:
The Myocardial Infarction pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Myocardial Infarction treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myocardial Infarction Treatment.
• Myocardial Infarction key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myocardial Infarction Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myocardial Infarction market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myocardial Infarction drugs and therapies
https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myocardial Infarction Pipeline Market Drivers
• Increasing research and development activities
• Increasing number of public initiatives and awareness program on cardiovascular disease

Myocardial Infarction Pipeline Market Barriers
• The lack of emergency care awareness
• The heterogeneity of patients, along with the duration of treatment and modalities

Scope of Myocardial Infarction Pipeline Drug Insight
• Coverage: Global
• Key Myocardial Infarction Companies: NuvOx Pharma, Ever Supreme Bio Technology, R-Pharm, Athera Biotechnologies, Celecor Therapeutics, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, and others
• Key Myocardial Infarction Therapies: NVX 308, UMSC01, RPH-104, ATH3G10, Zalunfiban, FDY-5301, Selatogrel, and others
• Myocardial Infarction Therapeutic Assessment: Myocardial Infarction current marketed and Myocardial Infarction emerging therapies
• Myocardial Infarction Market Dynamics: Myocardial Infarction market drivers and Myocardial Infarction market barriers

Request for Sample PDF Report for Myocardial Infarction Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Myocardial Infarction Report Introduction
2 Myocardial Infarction Executive Summary
3 Myocardial Infarction Overview
4 Myocardial Infarction- Analytical Perspective In-depth Commercial Assessment
5 Myocardial Infarction Pipeline Therapeutics
6 Myocardial Infarction Late Stage Products (Phase II/III)
7 Myocardial Infarction Mid Stage Products (Phase II)
8 Myocardial Infarction Early Stage Products (Phase I)
9 Myocardial Infarction Preclinical Stage Products
10 Myocardial Infarction Therapeutics Assessment
11 Myocardial Infarction Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Myocardial Infarction Key Companies
14 Myocardial Infarction Key Products
15 Myocardial Infarction Unmet Needs
16 Myocardial Infarction Market Drivers and Barriers
17 Myocardial Infarction Future Perspectives and Conclusion
18 Myocardial Infarction Analyst Views
19 Appendix
20 About DelveInsight

Related Reports:
Myocardial Infarction Market https://www.delveinsight.com/report-store/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myocardial Infarction-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Myocardial Infarction Epidemiology https://www.delveinsight.com/report-store/myocardial-infarction-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myocardial Infarction Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myocardial Infarction Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | NuvOx Pharma, Ever Supreme Bio Technology, R-Pharm, Athera Biotechnologies, here

News-ID: 3504569 • Views:

More Releases from DelveInsight Business Research

APAC Cervical Cancer Market Poised for Unprecedented Growth in the Next Decade by DelveInsight | Companies - ADC Therapeutics, Agenus, Akeso Biopharma, AstraZeneca, Betta Pharmaceuticals, Biocad, Bristol Myers Squibb, Exelixis, MORE
APAC Cervical Cancer Market Poised for Unprecedented Growth in the Next Decade b …
DelveInsight's "Cervical Cancer Patient Pool Analysis, Market Size and Market Forecast APAC, 2034" report delivers an in-depth understanding of Cervical Cancer, historical and forecasted epidemiology as well as the Cervical Cancer market trends in the India, China, South Korea, Taiwan, and Australia. The Cervical Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cervical Cancer market size from 2020
Biliary Tract Cancer Market Poised for Remarkable Growth in APAC Over the Next Decade | Key Players Include Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck
Biliary Tract Cancer Market Poised for Remarkable Growth in APAC Over the Next D …
(Albany, USA) DelveInsight's "Biliary Tract Cancer Market Size, Patient Pool Analysis, and Market Forecast APAC, 2034" report delivers an in-depth understanding of Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the India, China, South Korea, Taiwan, and Australia. The Biliary Tract Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted
Autoimmune Uveitis Market Set for Significant Growth in APAC by 2034 | Leading Companies: Tarsier Pharma, Eli Lilly, Oculis Pharma, Eyevensys, Priovant Therapeutics
Autoimmune Uveitis Market Set for Significant Growth in APAC by 2034 | Leading C …
(Albany, USA) DelveInsight's "Autoimmune Uveitis - Market Size, Patient Pool Analysis, and Market Forecast APAC, 2034" report provides comprehensive insights into the historical and projected patient burden, treatable patient population, and notable market trends across the APAC region (India, China, South Korea, Taiwan, and Australia), highlighting distinctions from established markets. The APAC Autoimmune Uveitis market report also offers insights into current treatment patterns, emerging prominent players, market shares of approved drugs,
APAC Atopic Dermatitis Market to Witness Unprecedented Growth Over the Next Decade, Reports DelveInsight | Key Players Include Boehringer Ingelheim, AbbVie, Bayer, Bristol-Myers Squibb, Novartis, LEO Pharma, Regeneron, Astellas Pharma, Pfizer
APAC Atopic Dermatitis Market to Witness Unprecedented Growth Over the Next Deca …
DelveInsight's "Atopic Dermatitis Patient Pool Analysis, Market Size and Market Forecast APAC, 2034" report delivers an in-depth understanding of Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the India, China, South Korea, Taiwan, and Australia. The Atopic Dermatitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atopic Dermatitis market size from 2020

All 5 Releases


More Releases for Myocardial

Myocardial Infarction Drugs Market
According to a new report published by Allied Market Research, titled, "Myocardial Infarction Drugs Market by Product Type (Analgesics, Antiplatelet Agents, Vasodilators, Thrombolytics, Anti-Thrombotic Agents, Glycoprotein IIb/IIIa Inhibitors, ' Adrenergic Blockers, Angiotensin Receptor Blockers, and Angiotensin Converting Enzyme Inhibitors) and by Distribution Channel (Hospital Pharmacies, Hospitals, Drug Stores, and Online Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2019-2026". The Global market size of Myocardial Infarction Drugs Market was $XX
Post-Myocardial Infarction Market rake higher revenue in 2025
Global Post-Myocardial Infarction Market: Overview The most common term used to refer to myocardial infarction is heart-attack. In this report, Transparency Market Research (TMR) delves into studying the factors causing the demand for post-myocardial infarction treatment. For the purpose of the study, TMR thus segments the global post-myocardial infarction market based on various parameters and then identifies opportunities prevalent across each of these segments. Besides this, the potential market threats are
Post-Myocardial Infarction Market Foretell Optimal Growth by 2025
Global Post-Myocardial Infarction Market: Overview The most common term used to refer to myocardial infarction is heart-attack. In this report, Transparency Market Research (TMR) delves into studying the factors causing the demand for post-myocardial infarction treatment. For the purpose of the study, TMR thus segments the global post-myocardial infarction market based on various parameters and then identifies opportunities prevalent across each of these segments. Besides this, the potential market threats are
Myocardial Ischemia Market to Record Ascending Growth
Myocardial ischemia is characterized by a specific condition, where there is an insufficient flow of blood to the heart muscle (myocardium) through coronary arteries. Due to an obstruction or constriction of the arteries, the heart is not able to pump oxygenated blood and other vital nutrients to the body efficiently and finally leads to destruction of the heart muscles. Blockage of an artery (due to atherosclerotic plaque), blood clots, heart
Post-Myocardial Infarction Market - Vendor Landscape & Forecast 2017 - 2025
Global Post-Myocardial Infarction Market: Overview The most common term used to refer to myocardial infarction is heart-attack. In this report, Transparency Market Research (TMR) delves into studying the factors causing the demand for post-myocardial infarction treatment. For the purpose of the study, TMR thus segments the global post-myocardial infarction market based on various parameters and then identifies opportunities prevalent across each of these segments. Besides this, the potential market threats are
Myocardial Ischemia - Pipeline Review, H1 2017
MarketResearchReports.Biz presents this most up-to-date research on "Myocardial Ischemia - Pipeline Review, H1 2017" Description Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Pipeline Review, H1 2017, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape. Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side